Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.

Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642.

PMID:
29435563
2.

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K.

JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924. No abstract available.

3.

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.

Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR.

Breast Cancer Res Treat. 2017 Nov;166(2):603-612. doi: 10.1007/s10549-017-4430-2. Epub 2017 Aug 8.

PMID:
28791495
4.

Supplemental Breast Cancer Screening: A Density Conundrum.

Tice JA, Kerlikowske K.

J Gen Intern Med. 2017 Jun;32(6):593-594. doi: 10.1007/s11606-017-3989-y. No abstract available.

5.

Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.

Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA; Athena Breast Health Network Investigators.

J Natl Cancer Inst. 2017 Jan 27;109(5). pii: djw290. doi: 10.1093/jnci/djw290. Print 2017 Jan. Review.

PMID:
28130475
6.

Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.

Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K.

PLoS One. 2017 Jan 20;12(1):e0168601. doi: 10.1371/journal.pone.0168601. eCollection 2017.

7.

Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.

Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL; Breast Cancer Surveillance Consortium.

J Natl Cancer Inst. 2016 Dec 31;109(5). pii: djw276. doi: 10.1093/jnci/djw276. Print 2017 May.

PMID:
28040694
8.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD.

Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. doi: 10.1016/j.anai.2016.10.028. Epub 2016 Dec 4.

PMID:
27923549
9.

Breast cancer risk prediction using a clinical risk model and polygenic risk score.

Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E.

Breast Cancer Res Treat. 2016 Oct;159(3):513-25. doi: 10.1007/s10549-016-3953-2. Epub 2016 Aug 26.

10.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.

JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.

PMID:
27533159
11.

Effectiveness and Value of Integrating Behavioral Health Into Primary Care.

Reed SJ, Shore KK, Tice JA.

JAMA Intern Med. 2016 May 1;176(5):691-2. doi: 10.1001/jamainternmed.2016.0804. Review. No abstract available.

PMID:
27064485
12.

Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ∼ FIT Cohort.

Dallal CM, Lacey JV Jr, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Veenstra TD, Xu X, Brinton LA; B∼FIT Research Group.

Horm Cancer. 2016 Feb;7(1):49-64. doi: 10.1007/s12672-015-0237-y. Epub 2016 Jan 4.

PMID:
26728471
13.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.

Tice JA, Kazi DS, Pearson SD.

JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248. Review. No abstract available.

PMID:
26662572
14.

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG.

JAMA Intern Med. 2016 Jan;176(1):65-73. doi: 10.1001/jamainternmed.2015.6011.

15.

Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial.

Livaudais-Toman J, Karliner LS, Tice JA, Kerlikowske K, Gregorich S, Pérez-Stable EJ, Pasick RJ, Chen A, Quinn J, Kaplan CP.

Breast. 2015 Dec;24(6):758-66. doi: 10.1016/j.breast.2015.09.009. Epub 2015 Oct 21.

16.

The effect of change in body mass index on volumetric measures of mammographic density.

Hart V, Reeves KW, Sturgeon SR, Reich NG, Sievert LL, Kerlikowske K, Ma L, Shepherd J, Tice JA, Mahmoudzadeh AP, Malkov S, Sprague BL.

Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1724-30. doi: 10.1158/1055-9965.EPI-15-0330. Epub 2015 Aug 27.

17.

Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.

Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K.

J Clin Oncol. 2015 Oct 1;33(28):3137-43. doi: 10.1200/JCO.2015.60.8869. Epub 2015 Aug 17.

18.

Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report.

Tice JA, Chahal HS, Ollendorf DA.

JAMA Intern Med. 2015 Sep;175(9):1559-60. doi: 10.1001/jamainternmed.2015.3348. Review. No abstract available.

PMID:
26167717
19.

Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women.

Falk RT, Dallal CM, Lacey JV Jr, Bauer DC, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Pfeiffer RM, Xu X, Veenstra TD, Brinton LA; B∼FIT Research Group.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1419-22. doi: 10.1158/1055-9965.EPI-15-0541. Epub 2015 Jun 23.

20.

Identifying women with dense breasts at high risk for interval cancer: a cohort study.

Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL; Breast Cancer Surveillance Consortium.

Ann Intern Med. 2015 May 19;162(10):673-81. doi: 10.7326/M14-1465.

Supplemental Content

Loading ...
Support Center